Antibody ID	ANI0YQQFV
Antibody Name	Anti-HER2 mAb
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG1
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (ERBB2)					Antigen Info

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 44.00% (Day 24)	High HER2 expression (HER2+++)
Method Description	All animals were euthanized before tumors reached 3000 mm3 or showed signs of impending ulceration. Mice were dosed IV via the tail vein with ADC conjugates A1-A4. A1 and A2 were dosed at 4 mg/kg.
In Vivo Model	MMTV-HER2 Fo5 CDX model (Trastuzumab resistant)
In Vitro Model	Breast cancer	MMTV-HER2 cells		Mus musculus

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 58.49% (Day 21)	Negative HER2 expression (HER2-)
Method Description	The nude mice were implanted with a human cancer cell line(MDA-MB-231) and the ADCs (10 mg/kg) were administered through intraperitoneal injection when the tumor volume reached about 100 cubic millimeters. The tumor volumes were monitored every 3 days and animals were sacrificed at the end of 21 days and the tumors were dissected and weighed.
In Vivo Model	MDA-MB-231 CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 63.00% (Day 24)	High HER2 expression (HER2+++)
Method Description	All animals were euthanized before tumors reached 3000 mm3 or showed signs of impending ulceration. Mice were dosed IV via the tail vein with ADC conjugates A1-A4. A1 and A2 were dosed at 4 mg/kg.
In Vivo Model	MMTV-HER2 Fo5 CDX model (Trastuzumab resistant)
In Vitro Model	Breast cancer	MMTV-HER2 cells		Mus musculus

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 88.00% (Day 24)	High HER2 expression (HER2+++)
Method Description	All animals were euthanized before tumors reached 3000 mm3 or showed signs of impending ulceration. Mice were dosed IV via the tail vein with ADC conjugates A1-A4. A1 and A2 were dosed at 4 mg/kg.
In Vivo Model	MMTV-HER2 Fo5 CDX model (Trastuzumab resistant)
In Vitro Model	Breast cancer	MMTV-HER2 cells		Mus musculus

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 24)	High HER2 expression (HER2+++)
Method Description	All animals were euthanized before tumors reached 3000 mm3 or showed signs of impending ulceration. Mice were dosed IV via the tail vein with ADC conjugates A1-A4. A1 and A2 were dosed at 4 mg/kg.
In Vivo Model	MMTV-HER2 Fo5 CDX model (Trastuzumab resistant)
In Vitro Model	Breast cancer	MMTV-HER2 cells		Mus musculus

Experiment 1 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.08 nM	Positive HER2 expression (HER2 +++/++)
Method Description	The cells wereincubated with serial dilutions of Duocarmycin-405 conjugated to anti-HER2 or a non-targetingantibody, Duocarmycin free drug and naked ant-HER2 controls for 6 days.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 100 nM	Negative HER2 expression (HER2 -)
Method Description	The cells wereincubated with serial dilutions of Duocarmycin-405 conjugated to anti-HER2 or a non-targetingantibody, Duocarmycin free drug and naked ant-HER2 controls for 6 days.
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

Experiment 1 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.88 nM	High HER2 expression (HER2 +++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.88 nM	High HER2 expression (HER2 +++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Experiment 1 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.55 nM	High HER2 expression (HER2 +++)
Method Description	Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.    Click to Show/Hide
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033

Ref 1	Intratumoral Payload Concentration Correlates with the Activity of Antibody-Drug Conjugates. Mol Cancer Ther. 2018 Mar;17(3):677-685. doi: 10.1158/1535-7163.MCT-17-0697. Epub 2018 Jan 18.
Ref 2	Covalent linkers in antibody-drug conjugates and methods of making and using the same.
Ref 3	Phosphate based linkers for intracellular delivery of drug conjugates; 2015-10-08.
Ref 4	Antibody drug conjugate and application thereof.